Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fenebrutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche Touts Phase II MS Data on Heels of Sanofi’s Late-Stage Stumbles
    Roche Touts Phase II MS Data on Heels of Sanofi’s Late-Stage Stumbles

    04 Sep 2024

    // BIOSPACE

    https://www.biospace.com/drug-development/roche-touts-phase-ii-ms-data-on-heels-of-sanofis-late-stage-stumbles

    BIOSPACE
    04 Sep 2024
    Share Share
    Roche's Fenebrutinib Shows Promise In Multiple Sclerosis
    Roche's Fenebrutinib Shows Promise In Multiple Sclerosis

    04 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/04/2940215/0/en/Roche-s-fenebrutinib-demonstrated-near-complete-suppression-of-disease-activity-and-disability-progression-for-up-to-48-weeks-in-patients-with-relapsing-multiple-sclerosis.html

    GLOBENEWSWIRE
    04 Sep 2024
    Share Share
    Genentech MS drug on partial US hold on liver enzyme elevations
    Genentech MS drug on partial US hold on liver enzyme elevations

    05 Dec 2023

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/genentechs-ms-drug-partial-hold-us-after-liver-enzyme-elevations-2-patients

    FIERCE BIOTECH
    05 Dec 2023
    Share Share
    Late-breaking data for Roche™s fenebrutinib show reduction in lesions
    Late-breaking data for Roche™s fenebrutinib show reduction in lesions

    13 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/13/2759987/0/en/Late-breaking-data-for-Roche-s-BTK-inhibitor-fenebrutinib-show-brain-penetration-and-significant-reduction-in-lesions-in-patients-with-relapsing-multiple-sclerosis.html

    GLOBENEWSWIRE
    13 Oct 2023
    Share Share
    Roche says new MS drug shown to reduce brain lesions
    Roche says new MS drug shown to reduce brain lesions

    18 May 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/roche-says-new-ms-drug-shown-reduce-brain-lesions-2023-05-17/

    REUTERS
    18 May 2023
    Share Share
    Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions
    Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions

    17 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230516005196/en

    BUSINESSWIRE
    17 May 2023
    Share Share